Trials / Completed
CompletedNCT02426372
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis
An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Qu Biologics Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response and remission in subjects with moderate to severe ulcerative colitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | QBECO SSI | QBECO Site Specific Immunomodulators |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2015-04-24
- Last updated
- 2017-08-24
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02426372. Inclusion in this directory is not an endorsement.